Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of Vactosertib plus durvalumab as third-line therapy in advanced gastric cancer
KCT0006353Phase 2Active, not recruiting
- Sponsor
- AstraZeneca
- Start
- Sep 2021
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of vactosertib, durvalumab in gastric cancer (GC), sponsored by AstraZeneca. Started Sep 2021; status: active, not recruiting.
02
Drugs
vactosertibdurvalumab
03
Conditions
gastric cancer (GC)
Beyond the preview
Go deeper on KCT0006353.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0006353.